Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

摘要: Metabolic hormones stabilize brain reward and motivational circuits, whereas excessive opioid consumption counteracts this effect may impair metabolic function. Here we addressed the role of processes in course agonist medication-assisted treatment for use disorder (OUD) with buprenorphine or methadone. Plasma lipids, hemoglobin A1C, body composition, oral glucose tolerance test (oGTT) Sweet Taste Test (STT) were measured buprenorphine- (n = 26) methadone (n = 32)- treated subjects OUD. On whole, both groups overweight obese insulin resistant; they displayed similar oGTT STT performance. As compared to methadone-treated subjects, those on had significantly lower rates syndrome (MetS) along better values high-density lipoproteins (HDL). Subjects with- vs. without MetS tended have greater addiction severity. Correlative analyses revealed that more exposure duration was associated HDL craving values. In contrast, worse triglycerides-, HDL-, blood pressure-, fasting glucose- A1C Buprenorphine appears produce beneficial HDL- effects and, contrary methadone, its derangements is not obvious. Our data call further research aimed at understanding distinctive features vis-a-vis their potential these drugs’ unique therapeutic profiles.